Gut and Liver最新文献

Is Vaccination a Risk Factor for Hepatitis B Reactivation? 疫苗接种是乙型肝炎再激活的危险因素吗？

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-18 DOI: 10.5009/gnl250132

Aslı Haykır Solay, Gülnur Kul

引用次数: 0

In-Hospital Hepatitis C Alarm System: A Strategy to Enhance Linkage to Care for Hepatitis C Virus Infection. 医院内丙型肝炎报警系统：加强丙型肝炎病毒感染护理联动的策略。

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-17 DOI: 10.5009/gnl250170

Jaehong Jeong, Chang Hyeong Lee, Byung Seok Kim, Jeong Eun Song

{"title":"In-Hospital Hepatitis C Alarm System: A Strategy to Enhance Linkage to Care for Hepatitis C Virus Infection.","authors":"Jaehong Jeong, Chang Hyeong Lee, Byung Seok Kim, Jeong Eun Song","doi":"10.5009/gnl250170","DOIUrl":"https://doi.org/10.5009/gnl250170","url":null,"abstract":"Background/aims: The World Health Organization aims to eliminate hepatitis C virus (HCV) by 2030; however, linkage to care rates remain suboptimal. To address this, an in-hospital HCV alarm system integrated into electronic medical records (EMRs) was implemented to increase confirmatory testing and referral rates.Methods: This retrospective study analyzed patients with positive anti-HCV antibody results at a tertiary hospital in Korea, comparing the pre-alarm period (August 2020-July 2022) with the post-alarm period (July 2022-May 2024). HCV RNA testing rates, liver clinic visits, and direct-acting antiviral (DAA) prescriptions were assessed. Multivariate logistic regression was performed to identify factors associated with the lack of HCV RNA testing implementation.Results: Among 941 patients who tested positive for anti-HCV antibodies, the proportion of patients who underwent HCV RNA testing significantly increased from 49.4% in the pre-alarm period to 67.8% in the post-alarm period (p<0.001). The rate of referral to liver specialists also showed an increasing trend (89.4% vs 93.2%), while DAA initiation rates remained similar (68.4% vs 72.0%). Multivariate analysis revealed that older age, surgical or emergency department admission, and non-liver-related testing indications were independent predictors of the lack of HCV RNA testing implementation.Conclusions: Implementation of an in-hospital HCV alarm system significantly increased HCV RNA testing rates, enhancing early diagnosis and linkage to care. While referral rates remained high, persistently low testing rates in emergency departments highlight the need for targeted interventions. A cost-effective, EMR-integrated alarm system may be a feasible strategy to support national HCV elimination efforts.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between Type 2 Diabetes and Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in South Korea. 2型糖尿病和胃肠道出血之间的关系：韩国一项基于全国人群的队列研究

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-17 DOI: 10.5009/gnl250109

Gihong Park, Bongseong Kim, Kyungdo Han, Hyunsoo Chung

{"title":"Association between Type 2 Diabetes and Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in South Korea.","authors":"Gihong Park, Bongseong Kim, Kyungdo Han, Hyunsoo Chung","doi":"10.5009/gnl250109","DOIUrl":"https://doi.org/10.5009/gnl250109","url":null,"abstract":"Background/aims: Type 2 diabetes mellitus (T2DM) is linked to an elevated risk of gastrointestinal bleeding (GIB), but the effects of diabetes duration and severity remain unclear. We investigated these associations in a nationwide Korean cohort.Methods: This retrospective cohort study used the Korean National Health Insurance database from individuals who underwent national health screening between 2009 and 2015. Participants were classified as having normal glucose, impaired fasting glucose (IFG), new-onset diabetes, diabetes <5 years, or diabetes ≥5 years. GIB was defined by fulfilling all three: hospitalization, red blood cell transfusion, and ICD-10 GIB codes. Because hemoglobin A1c data were unavailable, insulin treatment served as a surrogate for diabetes severity. Kaplan-Meier and Cox proportional hazards models were applied to estimate cumulative incidence and adjusted hazard ratios (aHRs), adjusting for medications and comorbidities.Results: Upper GIB risk increased progressively with diabetes duration: aHR 1.081 (95% confidence interval [CI], 1.008 to 1.159) for IFG; 1.265 (1.128 to 1.418) for new-onset diabetes; 1.561 (1.392 to 1.751) for diabetes <5 years; and 1.738 (1.578 to 1.915) for diabetes ≥5 years. Elevated risk was also observed among those receiving insulin. In contrast, diabetes duration was not significantly related to lower GIB: aHR 0.949 (95% CI, 0.830 to 1.085) for IFG; 1.150 (0.902 to 1.468) for new-onset diabetes; 1.202 (0.944 to 1.531) for diabetes <5 years; and 0.984 (0.792 to 1.224) for diabetes ≥5 years.Conclusions: Longer duration and greater severity of T2DM are associated with increased risk of upper GIB, whereas no significant association was found for lower GIB.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease. 韩国炎症性肠病患者从静脉注射转为皮下注射Vedolizumab的实际经验

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-17 DOI: 10.5009/gnl250188

Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon

{"title":"Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease.","authors":"Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon","doi":"10.5009/gnl250188","DOIUrl":"https://doi.org/10.5009/gnl250188","url":null,"abstract":"Background/aims: Subcutaneous (SC) vedolizumab (VDZ) has recently become available for patients with inflammatory bowel disease (IBD) in Korea. This retrospective observational study aimed to evaluate the clinical outcomes and safety of switching from intravenous (IV) to SC VDZ.Methods: Patients with IBD who switched from IV to SC VDZ between 2023 and 2024 were included. The primary outcome was the 24-week persistence rate of SC VDZ. Secondary outcomes included clinical factors associated with SC VDZ persistence, safety profiles, subsequent treatment courses after discontinuation of SC VDZ, and recapture success rate after reverting to IV VDZ.Results: A total of 101 patients with IBD (72 with ulcerative colitis [UC] and 29 with Crohn's disease) were included. After 24 weeks, 72 patients (71.3%) maintained SC VDZ. Corticosteroid use at switching was the strongest predictor of 24-week SC VDZ failure in both the overall IBD cohort (p=0.018) and in patients with UC (p=0.027) in multivariable analyses. Kaplan-Meier analysis showed that patients with UC with intensified IV dosing intervals (p=0.021), failure to clinical remission (p=0.038), or concomitant corticosteroid use at switching (p<0.001) were more likely to discontinue SC VDZ. Injection-site reactions occurred in 24 patients (23.8%). A total of 34 patients (33.7%) discontinued SC VDZ; 19 resumed IV VDZ; and 13 initiated another advanced therapy. The recapture success rate after reverting to IV VDZ was 73.7%, with higher success in those who discontinued because of injection-site reactions or poor adherence.Conclusions: SC VDZ persistence is significantly influenced by disease activity at the time of switching.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hidden Burden of Alcohol Use Disorder in MASLD and MetALD: Clinical and Nomenclatural Implications. 酒精使用障碍在MASLD和MetALD中的隐性负担：临床和命名意义。

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-15 DOI: 10.5009/gnl250414

Yuri Cho

引用次数: 0

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. 二肽基肽酶-4抑制剂与钠-葡萄糖共转运蛋白-2抑制剂治疗糖尿病合并脂肪变性肝病的疗效比较

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-15 Epub Date: 2025-07-18 DOI: 10.5009/gnl240616

Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim

{"title":"Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease.","authors":"Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim","doi":"10.5009/gnl240616","DOIUrl":"10.5009/gnl240616","url":null,"abstract":"Background/aims: There is currently insufficient evidence to recommend one oral hypoglycemic agent over another for diabetic patients to reduce hepatic steatosis or prevent advanced fibrosis. We aimed to evaluate the efficacy of dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes mellitus (DM) and metabolic dysfunction-associated steatotic liver disease (MASLD).Methods: This study included diabetic patients with steatotic liver disease who newly received either a DPP-4i or an SGLT-2i as a second-line treatment between 2014 and 2021 at a single tertiary hospital. MASLD was categorized as MASLD-H (radiologic steatosis with a hepatic steatosis index [HSI]>36) or MASLD-I (radiologic steatosis only). Changes in the HSI and fibrosis-4 (FIB-4) index were compared at 1 and 3 years after treatment initiation.Results: A total of 3,493 patients were consecutively enrolled, with 3,001 receiving DPP-4i treatment and 492 receiving SGLT-2i treatment. After applying propensity score matching, the SGLT-2i group showed a significantly greater reduction in the HSI than the DPP-4i group in the DM-MASLD population at both 1 year (DM-MASLD-H: DPP-4i vs SGLT-2i, -1.4% vs -3.7%, p<0.001; DM-MASLD-I: -1.3% vs -3.8%, p<0.001) and 3 years (DM-MASLD-H: -2.0% vs -4.0%, p=0.001; DM-MASLD-I: -2.4% vs -4.2, p=0.025). The FIB-4 indices of both groups increased; however, the increase at year 1 was more significant in the DPP-4i than in the SGLT-2i group (DM-MASLD-H: 11.4% vs 5.2%, p<0.001; DM-MASLD-I: 10.7% vs 4.3%, p=0.014).Conclusions: In patients with DM-MASLD, SGLT-2i treatment was associated with a greater reduction in hepatic steatosis and delayed fibrotic progression than DPP-4i treatment.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"758-769"},"PeriodicalIF":3.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Randomized Controlled Trial to Evaluate the Effect of Fibrin Glue on Bleeding after Gastric Endoscopic Submucosal Dissection. 一项评价纤维蛋白胶对胃内镜下粘膜剥离术后出血疗效的随机对照试验。

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-15 Epub Date: 2025-08-25 DOI: 10.5009/gnl250113

Tae-Se Kim, Tae-Jun Kim, Yang Won Min, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Poong-Lyul Rhee, Jae J Kim

{"title":"A Randomized Controlled Trial to Evaluate the Effect of Fibrin Glue on Bleeding after Gastric Endoscopic Submucosal Dissection.","authors":"Tae-Se Kim, Tae-Jun Kim, Yang Won Min, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Poong-Lyul Rhee, Jae J Kim","doi":"10.5009/gnl250113","DOIUrl":"10.5009/gnl250113","url":null,"abstract":"Background/aims: This study aimed to evaluate the effectiveness of fibrin glue application in reducing bleeding after endoscopic submucosal dissection (ESD) in the general patient population.Methods: This randomized controlled trial enrolled 262 patients who underwent ESD for gastric neoplasms. The participants were randomized into the fibrin glue group (n=133) or the control group (n=129). The primary outcome was the post-ESD bleeding rate, which was compared between the two groups. Additionally, exploratory subgroup analyses were conducted for high-risk patients, which included patients taking antithrombotic agents (ATAs) and patients with resected specimens measuring 4 cm or greater.Results: In the modified intention-to-treat population (n=252), the overall bleeding rate occurred in 10.7% of cases, including 10.3% of patients in the fibrin glue group and 11.1% of patients in the control group (p=0.839). In the per-protocol population (n=248), the bleeding rates were 10.3% in the fibrin glue group and 10.7% in the control group (p=1.000). Among ATA users, the overall bleeding rate was 18.0%, including 9.5% of patients in the fibrin glue group and 24.1% of patients in the control group (p=0.271). Among ATA users with specimens measuring 4 cm or larger, the overall bleeding rate was 18.4%, including 12.5% of patients in the fibrin glue group and 22.7% of patients in the control group (p=0.675).Conclusions: Routine application of fibrin glue after ESD did not significantly reduce postoperative bleeding. Although the results of subgroup analyses suggested a potential reduction in early bleeding among high-risk patients, these findings warrant further investigation.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"677-684"},"PeriodicalIF":3.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Associations of Tobacco, Alcohol, and Coffee Consumption with Upper and Lower Gastrointestinal Disease Risk: A Mendelian Randomization Study. 烟草、酒精和咖啡消费与上、下消化道疾病风险的关系：一项孟德尔随机研究

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-15 Epub Date: 2025-04-11 DOI: 10.5009/gnl240440

Fei Xue, Jiajing Xue, Bingbing Zhao, Shuai Zhu

{"title":"The Associations of Tobacco, Alcohol, and Coffee Consumption with Upper and Lower Gastrointestinal Disease Risk: A Mendelian Randomization Study.","authors":"Fei Xue, Jiajing Xue, Bingbing Zhao, Shuai Zhu","doi":"10.5009/gnl240440","DOIUrl":"10.5009/gnl240440","url":null,"abstract":"Background/aims: Gastrointestinal diseases present a significant global health challenge and greatly impact healthcare expenditures. Despite alcohol, tobacco, and coffee being universally recognized risk factors for various gastrointestinal disorders, the exact causal linkages have not been clarified because of the predominance of observational studies on this topic. Mendelian randomization (MR) was used to explore to what extent alcohol, tobacco, and coffee increase the risk of developing 13 upper and lower gastrointestinal diseases.Methods: Genetic data from large genome-wide association studies including GSCAN, FinnGen, UK Biobank, IIBDGC, GERA, and other consortia were used for both univariable and multivariable MR analyses. Single-nucleotide polymorphisms were used as instrumental variables and sensitivity analyses were conducted to identify potential pleiotropic effects.Results: Genetically predicted smoking was positively associated with esophageal cancer, Crohn's disease, gastric ulcer, irritable bowel syndrome, and gastroesophageal reflux risk, but was negatively associated with celiac disease risk. Alcohol intake was positively correlated with both esophageal cancer and chronic gastritis risk. These findings were confirmed by multivariable MR analyses, albeit with some variations. Coffee consumption was linked to esophageal cancer, but the association became nonsignificant after adjusting for hot beverage consumption.Conclusions: This comprehensive MR study suggests that alcohol and tobacco consumption are associated with the occurrence of several gastrointestinal diseases. These results support the need for public health initiatives to reduce smoking and alcohol abuse, with the aim of preventing both upper and lower gastrointestinal diseases.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"715-724"},"PeriodicalIF":3.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines. 丙型肝炎治愈后肝细胞癌监测的精确策略：关于指南的争论

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-15 Epub Date: 2025-09-08 DOI: 10.5009/gnl250187

Masaaki Mino, Eiji Kakazu, Tatsuya Kanto

{"title":"Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines.","authors":"Masaaki Mino, Eiji Kakazu, Tatsuya Kanto","doi":"10.5009/gnl250187","DOIUrl":"10.5009/gnl250187","url":null,"abstract":"Hepatitis C virus (HCV) clearance markedly reduces the risk of hepatocellular carcinoma (HCC); however, HCC continues to develop in a subset of patients, particularly in those with advanced fibrosis or cirrhosis. Leading hepatology societies, including Asian Pacific Association for the Study of the Liver, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, Korean Association for the Study of the Liver, Taiwan Association for the Study of the Liver, and Japan Society of Hepatology, have issued divergent guidelines for HCC surveillance after sustained virologic response, which reflects variations in regional patient populations, healthcare infrastructure, and policy priorities. While traditional risk stratification primarily centers on histological staging of fibrosis, an array of additional host-related factors, including age, sex, alcohol use, metabolic comorbidities, and genetic and epigenetic profiles, further influence individual HCC risks. Recently developed predictive models aim to improve risk discrimination and inform tailored surveillance intervals. Concurrently, health economic analyses support the continuation of surveillance in high-risk populations. Nonetheless, the optimal surveillance frequency and criteria for patient selection remain matters of ongoing debates. This review synthesizes current controversies across international guidelines, presents an evaluation of the supporting evidence for varied surveillance strategies, highlights emerging tools for individualized risk assessment, and discusses cost-effectiveness considerations to inform personalized, evidence-based HCC surveillance in the post-HCV cure landscape.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":"651-664"},"PeriodicalIF":3.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Nationwide Trend Analysis of Helicobacter pylori Treatment between 2010 and 2021 According to Revised Guidelines in Korea. 根据韩国修订指南，2010年至2021年全国幽门螺杆菌治疗趋势分析

IF 3.2 3区医学

Gut and Liver Pub Date : 2025-09-15 DOI: 10.5009/gnl250096

Seung In Seo, Su Youn Nam, Junwoo Jo, Chang Seok Bang, Moon Won Lee, Yoon Jin Choi, Woon Geon Shin

{"title":"A Nationwide Trend Analysis of Helicobacter pylori Treatment between 2010 and 2021 According to Revised Guidelines in Korea.","authors":"Seung In Seo, Su Youn Nam, Junwoo Jo, Chang Seok Bang, Moon Won Lee, Yoon Jin Choi, Woon Geon Shin","doi":"10.5009/gnl250096","DOIUrl":"https://doi.org/10.5009/gnl250096","url":null,"abstract":"Background/aims: Despite numerous global changes in Helicobacter pylori treatment guidelines over the past decade, no comprehensive nationwide trend analysis has been conducted. We aimed to investigate the annual trends in the use of H. pylori treatment regimens on the basis of hospital type and region to identify whether changes in prescription patterns aligned with the Korean guidelines updated in 2013 and 2020.Methods: Using data from Korean Health Insurance Review and Assessment database spanning from January 2010 to December 2022, we extracted the performance code for H. pylori diagnosis along with the drug combination code for H. pylori treatment.Results: We analyzed the annual trends in standard triple therapy (STT; n=664,748), bismuth quadruple therapy (BQT; n=151,828), concomitant therapy (CT; n=3,034), sequential therapy (SEQ; n=1,612), and salvage treatment. Overall, STT use declined, with the use of 7-day STT decreasing but the use of 10- and 14-day STT increasing. The use of BQT as a first-line treatment consistently increased, and non-BQT (i.e., CT and SEQ) use also increased sharply since 2019. The tendency to adhere to the guideline changes was more pronounced in primary care clinics. Salvage treatment with BQT after STT failure exhibited a declining trend from 2010 to 2017, followed by an increase since 2018. Salvage treatment with levofloxacin triple therapy after BQT failure increased over time.Conclusions: This long-term nationwide trend analysis revealed that real-world prescriptions for H. pylori treatment generally corresponded to the updated guidelines. Efforts are needed to disseminate the revised guidelines to achieve higher compliance rates.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0